You may have seen our announcement this morning of a second molecular glue collaboration with Genentech, which comes out of our unique approach leveraging induced proximity to deliver important medicines for the future. Induced proximity opens the door not only for new small-molecule modalities like molecular glues, but also for new large-molecule modalities, as is the case for our A-KinesTM and Multimodal Cell Engagers that focus on harnessing the power of the immune system with exquisite selectivity, and in multiple ways. At Orionis, we are working to pioneer a new era of medicine by making new connections between proteins or proteins and cells, thereby reprogramming signaling networks to trigger powerful biological events with therapeutic outcomes. For more information on the Genentech small-molecule molecular glue collaboration, please find our press release is here: orb.ink/gne-2025 #Oncology #Cancer #MolecularGlue #DrugDiscovery #CancerResearch #Biotech #InducedProximity #Cytokines #CellEngagers #ImmunoOncology #Immunotherapy

Thrilled to announce today our second multi-year collaboration with @genentech, which will focus on discovery and development of small-molecule monovalent glue medicines to fight cancer. With this collaboration we will receive a $105 million upfront payment as well as potential subsequent milestone payments. We are excited by the possibilities in potentially transforming cancer treatment with molecular glues. You can learn more in our press release: orb.ink/gne-2025 #Oncology #Cancer #Genentech #MolecularGlue #DrugDiscovery

Top Alliances Of 2023 - Vote for @OrionisBio / @genentech. Bringing precision drug design to battle cancer and other life threatening diseases 👏invivo.citeline.com/IV148673…

Thank you @tfadell for your support. We’re very excited to have you join the board and help us navigate the future! And a big thank you also to @TwoCentz for having been an incredibly supportive board member over the past years, and for continuing to be part of the journey. Exciting times ahead!

Two important company announcements today! 1: First cancer patient dosed in a Phase 1 immunotherapy clinical trial of ORB-011, a first-in-class targeted interferon A-Kine®. 2: @tfadell, Founder and Principal at Build Collective, joins Orionis Board of Directors. Learn more here: orb.ink/2023_clinic #immunotherapy #cancerresearch #clinicaltrials #solidtumors

Congratulations to #TBCPartner @orionisbio who last week announced a partnership with @genentech to leverage its Allo-Glue™ platform for the discovery of small molecule monovalent glues. (1/3)

Great deep-dive on everything @OrionisBio, featuring our CEO Nikolai Kley and @bradloncar for @BiotechTVHQ. Over 20 minutes you'll hear about how our drug discovery and design platforms, inspired by powerful biological mechanisms present in nature, can reach undruggable targets with molecular glues, and restart a stalled Cancer Immunity Cycle with targeted cytokines. biotechtv.com/post/orionis-b…

Very cool to see a second collaboration on Molecular Glue discovery with @OrionisBio, here with @roche @genentech. Niko and friends are creative scientists, terrific partners at the bench. Proud to see this platform expand its potential impact. orionisbio.com/2023/09/genen…

Genentech gets gluey, paying $47M upfront to Orionis for degrader discovery deal endpts.com/genentech-gets-gl…

📢 More news from the #VIBspinoff community: @OrionisBio announces collaboration with @genentech to discover and develop molecular glue class medicines. Applications are possible in major disease areas such as #oncology and #neurodegeneration. 👇 vibbio.tech/46cicvS

Today we announced a collaboration with @genentech to discover and develop molecular glue class medicines using our Allo-Glue™ platform. Learn more: orb.ink/2023_AG

Today at 5:15pm ET, CEO Niko Kley, Ph.D., will be sharing a presentation on our use of modified #cytokines to target immune receptors for selective responses to cancer at @HansonWade’s Annual Induced Proximity-Based Drug Discovery Summit. Learn more: bit.ly/3OgTtQX

CEO Niko Kley, Ph.D., will present on “Using Modified #Cytokines to Target Immune Receptors for Selective Response Towards Cancer” at @HansonWade’s Annual Induced Proximity-Based Drug Discovery Summit next Wednesday at 5:15pm ET in Boston, MA. Learn more: bit.ly/3OgTtQX

Thursday at 9am ET, our CEO Niko Kley will present on the reprogramming of the cancer immunity cycle with cis-acting cytokines at @HansonWade’s Cytokine-Based Drug Development Summit in Boston, MA. Learn more: bit.ly/3OWMNbi #cytokines #cancerresearch #drugdevelopment

Orionis CEO Niko Kley will be presenting at @HansonWade’s 4th Annual Cytokine-Based Drug Development Summit in Boston, MA next week. His presentation will cover the reprogramming of the cancer immunity cycle with cis-acting cytokines. Learn more: bit.ly/3OWMNbi

More fireworks after 6 pm at #AACR23: #CICR townhall with 3 awesome talks about molecular glue degraders. Michael Rapé (@RapeLab), Riccardo Sabatini (@OrionisBio) & Mary Matyskiela (@neomorphinc). Chaired by Ben Ebert (@DFCI_ChemBio). Glueing everybody to their seats. @AACR #TPD